Noncanonical Role of the PDZ4 Domain of the Adaptor Protein PDZK1 in the Regulation of the Hepatic High Density Lipoprotein Receptor Scavenger Receptor Class B, Type I (SR-BI)

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

Citation
Tsukamoto, K., T. E. Wales, K. Daniels, R. Pal, R. Sheng, W. Cho, W. Stafford, J. R. Engen, M. Krieger, and O. Kocher. "Noncanonical Role of the PDZ4 Domain of the Adaptor Protein PDZK1 in the Regulation of the Hepatic High Density Lipoprotein Receptor Scavenger Receptor Class B, Type I (SR-BI)." Journal of Biological Chemistry 288, no. 27 (July 5, 2013): 19845–19860.

As Published
http://dx.doi.org/10.1074/jbc.M113.460170

Publisher
American Society for Biochemistry and Molecular Biology (ASBMB)

Version
Author’s final manuscript

Citable link
http://hdl.handle.net/1721.1/87732

Terms of Use
Article is made available in accordance with the publisher’s policy and may be subject to US copyright law. Please refer to the publisher’s site for terms of use.
Molecular analysis of the PDZ4 domain of PDZK1

Non-Canonical Role of the PDZ4 domain of the Adaptor Protein PDZK1 in the Regulation of the Hepatic HDL receptor SR-BI.

Kosuke Tsukamoto1, Thomas E. Wales2, Kathleen Daniels3, Rinku Pal3, Ren Sheng4, Wonhwa Cho4, Walter Stafford5, John R. Engen2, Monty Krieger1 and Olivier Kocher3

1Department of Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, 2Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, 3Department of Pathology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, 4Department of Chemistry, University of Illinois at Chicago, Chicago, IL 60607, 5Boston Biomedical Research Institute, 64 Grove St., Watertown, MA 02472.

Running title: Molecular analysis of the PDZ4 domain of PDZK1.

Correspondence should be addressed to either: Olivier Kocher, MD, PhD, Department of Pathology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215. Phone: (617) 667-3598, Fax: (617) 667-3591. E-mail: okocher@bidmc.harvard.edu or Monty Krieger, PhD, Biology Department, Massachusetts Institute of Technology, Room 68-483, 77 Massachusetts Avenue, Cambridge, MA 02139. Phone: (617) 253-6793 Fax: (617) 258-5851 E-mail: krieger@mit.edu

Keywords: PDZK1, PDZ domains, SR-BI, Cholesterol, HDL.

Background: PDZK1 (four PDZ domains) regulates the hepatic HDL receptor SR-BI. Results: PDZK1’s PDZ2 and PDZ3 domains are not required, whereas PDZ4 is – possibly because PDZ4 mediates membrane binding. Conclusion: Regulation of SR-BI via PDZK1’s PDZ domains is complex. Significance: Combined canonical (target peptide binding) and non-canonical (peptide binding independent) PDZ domain functions can result in optimal activity of a PDZ domain-containing adaptor protein.

SUMMARY

The four PDZ (PDZ1-PDZ4) domain-containing-adaptor protein PDZK1 controls the expression, localization and function of the HDL receptor SR-BI in hepatocytes in vivo via a PDZ4-dependent mechanism involving the binding of SR-BI’s cytoplasmic carboxy terminus to the canonical peptide binding sites of the PDZ1 or PDZ3 domains (no binding to PDZ2 or PDZ4). Using transgenic mice expressing in the liver domain deletion (∆PDZ2 or ∆PDZ3), domain replacement (PDZ2→1) or target peptide binding-negative (PDZ4[G389P]) mutants of PDZK1, we found that neither PDZ2 nor PDZ3, nor the canonical target peptide binding activity of PDZ4 were necessary for hepatic SR-BI regulatory activity. Immunohistochemical studies established that the localization of PDZK1 on hepatocyte cell-surface membranes in vivo is dependent on its PDZ4 domain and the presence of SR-BI. Analytical ultracentrifugation and hydrogen deuterium exchange mass spectrometry suggested that the requirement for PDZ4 for localization and SR-BI regulation is not due to PDZ4-mediated oligomerization or induction of conformational changes in the PDZ123 portion of PDZK1. However, Surface Plasmon Resonance analysis showed that PDZ4, but not the other PDZ domains, can bind vesicles that mimic the plasma membrane. Thus, PDZ4 may potentiate PDZK1’s regulation of SR-BI by promoting its lipid-mediated attachment to the
cytoplasmic membrane. Our results show that not all of the PDZ domains of a multi-PDZ domain-containing adaptor protein are required for its biological activities and that both canonical target peptide binding and non-canonical (peptide binding independent) capacities of PDZ domains may be employed by a single such adaptor for optimal in vivo activity.

The expression, localization and function of membrane-associated proteins, including cell surface receptors, are often regulated by cytoplasmic adaptor proteins (1). One of the largest protein interaction domain families is the PDZ (PSD-95, Discs-large, ZO-1) family. Indeed, human PDZ domain-containing proteins are encoded by 152 genes comprising 267 PDZ domains (2,3). PDZ domains typically bind to the C-termini of their binding partners (1) via a well-defined binding pocket (4). PDZ domain-containing proteins play prominent roles in regulating the activity of their targets and signal transduction. A large number of these proteins contain multiple PDZ domains and therefore are able to serve as scaffold proteins to coordinate complex cellular functions. PDZK1 (5), a 519-amino acid cytoplasmic protein, is an example of such a protein as it contains four PDZ domains. It interacts with several membrane-associated proteins such as cell surface receptors and ion channels (2,6). One of these PDZK1 interacting proteins is the HDL receptor scavenger receptor class B type I (SR-BI) (7-9).

SR-BI is a 509 amino-acid cell surface glycoprotein with a large extracellular loop, two trans-membrane domains and short cytoplasmic amino- and carboxy-termini (10). It plays a major role in the transfer of cholesterol from HDL-particles into cells (10,11) by a process called selective uptake (12). Inactivation of the SR-BI gene in mice results in a major increase in plasma cholesterol (~2.2 fold) in the form of abnormally large HDL particles (13). In apoE knockout (KO) mice (14,15), the additional inactivation of the SR-BI gene leads to occlusive atherosclerosis, myocardial infarction and premature death (16,17). Ikemoto et al first showed that the carboxy-terminal tail of SR-BI binds to the N-terminal PDZ domain (PDZ1) of PDZK1 (7). We confirmed this high affinity (K_d=2.6 μM) binding in vitro, and also found lower affinity (K_d=37.0 μM) binding of SR-BI’s C-terminus to the third PDZ domain (PDZ3) of PDZK1, but no binding to PDZ2 or PDZ4 (18,19). The C-terminus of SR-BI binds to the canonical carboxylate binding loops of PDZ1 and PDZ3 (18,19), the binding site used by most PDZ domains to bind their target peptides (20).

Inactivation of the PDZK1 gene in mice leads to a dramatic decrease in steady state SR-BI protein expression in some tissues (~95% decrease in hepatocytes, ~50% in small intestinal epithelial cells), but not others (e.g., steroidogenic organs or endothelial cells) (8,21,22). As a result, PDZK1 KO mice show an increase of plasma cholesterol (~1.7 fold) in the form of abnormally large HDL particles that is similar to, but not as severe as, that seen in SR-BI KO mice (8). Because we have been unable to robustly reproduce the PDZK1-dependence of SR-BI in cultured cells (unpublished results), we have analyzed the functional consequences of altering PDZK1’s structure on its function using PDZK1 transgenes expressed in hepatocytes of wild-type (WT) or PDZK1 KO mice (18,19,23,24). Analyses of a variety of such transgenic mice established that PDZK1 controls SR-BI’s expression, localization and function. For example, we introduced point mutations in PDZK1 that disrupt the binding of either the PDZ1 or PDZ3 domains to SR-BI’s C-terminus and showed that only one active SR-BI binding PDZ domain is necessary for normal PDZK1-dependent regulation of hepatic SR-BI (18,19). A C-terminally truncated PDZK1 containing only the first three N-terminal PDZ domains (PDZ123) is unable to restore full, normal expression and function of SR-BI in PDZK1 KO mice, while a truncated PDZK1 transgene containing all four PDZ domains (PDZ1234), but missing the carboxy-terminal fifty-eight amino acids of the protein, is fully functional (23). These findings suggested that the fourth PDZ domain (PDZ4), which does not bind directly to SR-BI’s C-terminus (19), performs a critical role in promoting normal SR-BI function.

In the current study, we have further explored the in vivo roles of PDZK1’s PDZ2, PDZ3 and PDZ4 domains in regulating hepatic SR-BI expression and activity. Using transgenic mice, we have determined that the PDZ2 or PDZ3 domains can be deleted from PDZK1 without
compromising PDZK1’s ability to mediate normal hepatic SR-BI expression or function. Furthermore, we have determined using immunohistochemistry that the PDZ4 domain is necessary for normal cell surface membrane association of PDZK1. However, this function of PDZ4 is not mediated by classical canonical binding to the C-terminus of a target protein, but rather by direct binding of this PDZ domain to plasma membrane lipids as demonstrated using Surface Plasmon Resonance (SPR). Biophysical analyses of recombinant PDZK1 in vitro demonstrated that PDZ4 is not responsible for protein oligomerization, and does not alter the backbone conformation of the PDZ123 domains (hydrogen/deuterium exchange mass spectrometry, HXMS). These studies raise the possibility that PDZ4 may be required for normal PDZK1-mediated regulation of hepatic SR-BI in vivo because of its ability to target PDZK1 to the inner leaflet of the plasma membrane of hepatocytes.

Experimental Procedures

**Generation of PDZK1 cDNAs encoding proteins with amino acid substitutions or PDZ domain substitution/deletions:** Vectors encoding PDZK1 with a Y388A, G389P or G380A single residue substitutions or Y388G + G389P, Y388A + G380A, or Y388A + G389P double residue substitutions within PDZ4’s carboxylate binding loop were produced using a previously described wild-type PDZK1/pLiv-LE6 or PDZK1/pCDNA3.1 recombinant plasmids (24) and the QuikChange site-directed mutagenesis kit (Stratagene) according to the manufacturer’s protocol. Oligonucleotide primers containing the corresponding mutations were synthesized and PAGE purified by Integrated DNA Technologies (IDT). A PDZK1 cDNA gene in which the second PDZ domain (PDZ2, residues 133-212) was replaced by the PDZ1 sequence (residues 7-86, resulting in two PDZ1 domains in tandem (PDZ2→1)), as well as PDZK1 cDNA genes in which either the PDZ2 (ΔPDZ2, residues 133-212) or PDZ3 (ΔPDZ3, residues 241-319) domains were deleted were synthesized by IDT. KpnI-XhoI DNA fragments corresponding to each of these mutant PDZK1 constructs were subcloned into the pLiv-LE6 plasmid (24), which was kindly provided by Dr. John M. Taylor (Gladstone Institute of Cardiovascular Disease, University of California, San Francisco), and contains the promoter, first exon, first intron, and part of the second exon of the human apoE gene, and the polyadenylation sequence, and a part of the hepatic control region of the apoE/C-I gene locus (25). The sequences of the resulting plasmids were confirmed by DNA sequencing.

**Recombinant protein production and purification:** We generated cDNAs encoding individual PDZ domains, full-length or truncated PDZK1 proteins, all with either wild-type sequences, single or double point mutations. A cDNA encoding full-length WT PDZK1 was used as template to generate WT PDZ3- and PDZ4-encoding PCR products corresponding to residues 241-348 (108 residues) and 376-484 (109 residues) of PDZK1 and truncated PDZK1 containing the first three PDZ domains (PDZ123) corresponding to the first 359 amino acids of PDZK1, or containing the four PDZ domains of PDZK1 (458 amino acids), but lacking the 61 carboxy-terminal amino-acids of the protein (PDZ1234). cDNAs encoding full-length PDZK1 with single or double residue substitutions in the PDZ4 domain of PDZK1 (see above) were used as templates to generate mutated PDZ4 domains containing the substitutions described above.

All of the cDNAs were cloned into pGEX-4T-3 and expressed in *E. coli* JM109 cells to produce glutathione-S-transferase fusion proteins. The expressed proteins were purified on glutathione-Sepharose 4B (GE Healthcare) and released by digestion with thrombin. All recombinant proteins contained a Gly-Ser dipeptide encoded by the cloning vector at the N-terminus that is not normally present in PDZK1 and generated as the N-terminus by thrombin cleavage. The recombinant proteins were further purified by fast protein liquid chromatography (FPLC) using Superdex S75 or S200 columns (GE Healthcare) in a buffer containing 150 mM NaCl, 25 mM Tris-pH 8.0 at 4 °C under reducing conditions (0.5 mM tris (2-carboxyethyl) phosphine (TCEP)), and were shown to be homogeneous using SDS-PAGE.

**Isothermal titration calorimetry (ITC):** Binding of recombinant proteins to the C-terminal heptapeptide of transient receptor potential cation channel subfamily C member 5
Molecular analysis of the PDZ4 domain of PDZK1

(TRPC5) (EQVTTRL, ‘target peptide’) was measured using a VP-ITC microcalorimeter (GE Healthcare). The TRPC5 peptide was synthesized and purified by HPLC at the Tufts University Core Facility (Boston). Briefly, 1.0 mM of the target peptide was titrated against the recombinant proteins at a concentration of 0.03 mM in a buffer containing 150 mM NaCl, 25 mM Tris-pH 8.0 at 20 °C under reducing conditions (0.5 mM tris (2-carboxyethyl) phosphine (TCEP)). Titration curves were analyzed and $K_d$ values determined using ORIGIN 7.0 software (Origin Lab).

Analytical ultracentrifugation:
Sedimentation velocity analyses were performed on a Beckman Instruments Optima XL-I Analytical Ultracentrifuge with Rayleigh optics at 50,000 rpm and three loading concentrations (1.803, 0.453 and 0.212 mg/mL). Interference optics were used, and time difference methods were used to correct for optical background systematic noise as previously described (26-29).

Hydrogen/deuterium exchange mass spectrometry (HXMS):
Deuterium Exchange reactions:
Deuterium labeling was initiated with a 15-fold dilution of an aliquot (60 picomoles PDZ1234 or PDZ123) of each of the purified protein stock solutions into a $D_2O$ buffer containing 25 mM Tris pH 8.03, 150 mM NaCl, 0.5 mM TCEP (buffer A). After incubation at 21°C for either 10 sec, 10 min, 1 hr or 4 hr, the labeling reaction was quenched with the addition of an equal volume of quench buffer (150 mM potassium phosphate, pH 2.54).

Online protein digestion and mass analysis. Immediately following the acid quench, samples were injected into a nanoACQUITY with HDX technology (30) for online pepsin digestion with a 2.1 x 30 mm Poroszyme® immobilized pepsin cartridge (Life Technologies™). The peptides were trapped and desalted on a VanGuard Pre-Column trap (2.1 x 5 mm, ACQUITY UPLC BEH C18, 1.7 µm) for 3 min. Peptides eluted from the trap using a 5-35 % gradient of acetonitrile over 6 min at a flow rate of 60 µL/min and were separated using an ACQUITY UPLC HSS T3, 1.8 µm, 1.0 x 50 mm column. Peptides from an unlabeled protein sample were identified in triplicate using ProteinLynx 2.5 Global Server (PLGS) searches of a protein database including analyte proteins as well as porcine pepsin A1, A2.

All mass spectra were acquired using a Waters QTOF Premier mass spectrometer. Each deuterium labeling experiment was performed in duplicate. In this instrumental setup, the error of measuring the deuterium incorporation for each peptide was at or below +/- 0.2 Da (31). Typically, differences of relative deuterium incorporation less than ~0.4 Da are considered to be within the error of measurement (31-33). All mass spectra were processed using DynamX software (Waters). The data were not corrected for back exchange and are therefore reported as relative values (34,35). The relative differences in deuterium incorporation for each common peptide in PDZ1234 and PDZ123 were calculated by subtracting the relative deuterium incorporation for PDZ123 from PDZ1234 (PDZ1234 – PDZ123 = Relative difference).

Lipid vesicle preparation and surface plasmon resonance (SPR) analysis: Plasma membrane (PM)-mimetic vesicles (POPC/POPE/POPS/PI/cholesterol/PtdIns(4,5)P2 (12:35:22:8:22:1)) and control 100% POPC vesicles were prepared as previously described (36). All SPR measurements were performed in 20 mM Tris-HCl (pH 7.4) containing 160 mM NaCl at 23°C using a lipid-coated L1 chip in the BIACORE X system as previously described (37). PM-mimetic and POPC vesicles were used to coat the active and control surfaces, respectively. Vesicles were injected at 5 µl/min onto the corresponding sensor chip surfaces to yield the identical resonance units (RU), ensuring the equal concentration of the coated lipids (PM-mimetic and control POPC). Equilibrium measurements were performed at a flow rate of 5 µl/min, which allowed enough time for the $R$ values of the association phase to reach near equilibrium levels ($R_{eq}$) (36). Each sensorgram was background-corrected by subtracting the control (POPC) surface response from the active (PM-mimetic) surface response. A minimum of 5 different protein concentrations (0.25, 0.5, 1.0, 3.0 and 5 µM) were injected to collect a set of $R_{eq}$ values that were plotted against the protein concentrations ($P_o$). An apparent dissociation constant ($K_d$) was then determined by nonlinear least squares analysis of the binding isotherm using the following equation: $R_{eq} = R_{max} / (1 + K_d/P_o)$ where $R_{max}$ indicates the maximal $R_{eq}$ value. Since the concentration of lipids coated on the sensor chip
cannot be accurately determined, $K_d$ is defined as $P_o$ yielding half-maximal binding with a fixed lipid concentration. The measurement was repeated at least three times to determine average and standard deviation values.

**Animals:** All animal experiments were performed according to IACUC guidelines. All mice (25:75 FVB/N:129Sv/EV genetic background) were maintained on a normal chow diet (38) and ~6-8 week old male mice were used for experiments. All procedures on transgenic and non-transgenic mice were performed in accordance with the guidelines of the Beth Israel Deaconess Medical Center and the Massachusetts Institute of Technology Committee on Animal Care.

PDZK1 KO mice, PDZK1 KO mice expressing a PDZ1234 transgene, founder 1159 (approximately 10-fold greater PDZ1234 protein than PDZK1 in WT liver) and PDZK1 KO mice expressing a PDZ123 transgene, founder 644 (approximately 8-fold greater PDZ1234 protein than PDZK1 in WT liver) were generated as previously described (23,38). Mice on a 50:50 C57Bl/6:129 background with heterozygous or homozygous null mutations of SR-BI were generated as previously described (13). Previously unreported founder transgenic animals in an FVB/N genetic background were generated using the PDZ2→1, ΔPDZ2, ΔPDZ3 and full length PDZK1 containing a G$^{389}P$ mutation in the PDZ4 domain (PDZK1[G$^{389}P$]) pLiv-LE6 expression vectors described above (see also Fig. 1, D-G). The pLiv-LE6 plasmid, kindly provided by Dr. John M. Taylor (Gladstone Institute of Cardiovascular Disease, University of California, San Francisco), contains the promoter, first exon, first intron, and part of the second exon of the human apoE gene, and the polyadenylation sequence, and a part of the hepatic control region of the apoE/C-I gene locus (25).

The transgenic expression vectors were digested with SacI/SpeI and the resulting 6.3 to 6.5 kb constructs were used to generate transgenic mice using standard procedures (39). Transgenic animals were identified by PCR performed on tail DNA using the following oligonucleotide primers: one within the PDZK1 cDNA and one corresponding to the 3' end of the human apoE gene sequence included in the cloning vector: for PDZ2→1 and ΔPDZ3: CAATGGTGCTTTTGGACAAG and AGCGAGATGCCTGAAGACCTTGTTGA, for ΔPDZ2: GCAGAGGCGCTGGCTGAAGAC and GCCAGCAGATGCCTGAACCTTGTTGAATC and for PDZK1[G$^{389}P$]: GAGGCAGCTGGCTTGAAGAAC and AGCGAGATGCCTGAACCTTGTTGA.

Animals expressing PDZK1 transgenic mutants were crossed with PDZK1 KO mice (129Sv/EV background). Heterozygous pups expressing the transgenes were crossed with WT and PDZK1 KO mice to obtain transgenic and control non-transgenic WT and PDZK1 KO mice, thus ensuring that the mixed genetic backgrounds of experimental and control mice in each founder line were matched. PDZK1 KO mice were genotyped as previously described (38). Two independent founder lines for each construct were generated.

**Blood and tissue sampling, processing, and analysis:** Plasma and liver samples were collected and processed and total plasma cholesterol levels and size fractionated fast protein liquid chromatography (FPLC) cholesterol profiles were obtained as previously described (24). Plasma cholesterol results presented here for transgenic mice are pooled from data collected from animals derived from the different founder transgenic animals because the results obtained were not significantly different between founders expressing the same transgene.

For immunoblotting, protein samples (~30 µg) from total liver lysates were fractionated by SDS-PAGE, transferred to nitrocellulose membranes and incubated with either a rabbit polyclonal SR-BI antibody (mSR-BI$^{495-112}$) (1:1000) or a rabbit polyclonal PDZK1 antibody (1:30000) (24), followed by an anti-rabbit IgG conjugated to horseradish peroxidase (Invitrogen, 1:10000), and visualized by ECL chemiluminescence (GE Healthcare). Immunoblotting using a polyclonal anti-ε-COP antibody (1:5000) (40) was used to control for small variations in loading. The relative amounts of proteins were determined quantitatively using a Kodak Image Station 440 CF and Kodak 1D software.

**Immunoperoxidase analysis:** Livers were harvested, fixed, frozen, and 5 µm sections were stained with an anti-mPDZK1 (23) or anti-mSR-BI$^{495-112}$ antibody and biotinylated anti-rabbit...
Molecular analysis of the PDZ4 domain of PDZK1

In IgG, visualized by immunoperoxidase staining, and counterstained with Harris modified hematoxylin, as described previously (8).

**Statistical Analysis:** Data are shown as the means ± standard deviations. Statistically significant differences were determined by either pairwise comparisons of values using the unpaired t test, with (if variances differed significantly) or without Welch’s correction, or by one-way ANOVA followed by the Tukey-Kramer multiple comparison post-test when comparing three or more variables. Mean values for experimental groups are considered statistically significantly different for P < 0.05 for both types of tests.

**Results**

**Roles of the PDZ2 and PDZ3 domains on the regulation of hepatic SR-BI.** To examine the influence of the PDZ2 and PDZ3 domains of PDZK1 on hepatic SR-BI in vivo, we generated transgenic (Tg) mice expressing three types of essentially liver-specific PDZK1 mutant transgenes. In these mutants: 1) the PDZ2 domain was replaced by PDZ1 (PDZ2→1, Fig. 1D) resulting in two successive PDZ1 domains as the two first PDZ domains of PDZK1 (PDZ2→1); 2) the PDZ2 domain (residues 133-212) was deleted from the full length PDZK1 protein (ΔPDZ2, Fig. 1E); and 3) the PDZ3 domain (residues 241-319) was deleted from the full length PDZK1 protein (ΔPDZ3, Fig. 1F). We generated two founder lines for PDZ2→1 (designated 8418 and 8419), two founder lines for ΔPDZ2 (designated 8421 and 8423), and two founder lines for ΔPDZ3 (designated 8440 and 8442), which were used to generate background matched wild-type (WT-Tg) and PDZK1 KO (KO-Tg) transgenic mice on a mixed FVB/129SvEv background. Background matched nontransgenic WT and PDZK1 KO mice were used as controls for each founder.

For each group of WT-Tg and KO-Tg mice and their nontransgenic controls, we determined the hepatic expression levels of PDZK1 and SR-BI proteins by quantitative immunoblotting (panels A in Fig. 2-4, e-COP was used as a loading control). The ratios of band intensities (transgenic/nontransgenic) are shown in Table I. The relative steady state levels of PDZK1 transgene encoded proteins varied between 2.5±0.5- and 17.2±4.7-fold greater than that of endogenous PDZK1 in nontransgenic WT mice (most >5-fold). Thus, there was substantial overexpression of the transgene encoded hepatic PDKZ1 proteins relative to that of the endogenous PDZK1 protein in nontransgenic WT mice. We also measured plasma total cholesterol levels (panels B in Figs. 2-4), the size distribution of plasma lipoproteins (FPLC lipoprotein cholesterol profiles, panels C in Fig. 2-4) and the distribution of SR-BI protein expression determined by immunoblotting (panels A in Figs. 2-4, and Table I). Expression of the PDZ2→1 protein resulted in a small, but significant, increase in hepatic SR-BI protein expression (2.16±0.32-fold, p = 0.01) None of the three transgenes altered the sinusoidal membrane-associated distribution of SR-BI determined by immunohistochemistry (Fig. 5, panels A, C, E and G), plasma cholesterol levels (left panels B in Figs. 2-4) or lipoprotein cholesterol size distribution profiles determined by FPLC (circles in panels C of Figs. 2-4). Thus, these mutated transgenes did not produce substantial dominant negative effects when overexpressed in WT mice (an example of a dominant negative truncated PDZK1 is described in (24)).

**Effects of mutant PDZK1 constructs in Wild-Type (WT) mice.** In transgenic WT (WT-Tg) mice relative to nontransgenic WT mice, expression of the ΔPDZ2 and ΔPDZ3 protein had no significant influence on the levels of hepatic SR-BI protein expression determined by immunoblotting (panels A in Figs. 2-4, and Table I). Expression of the PDZ2→1 protein resulted in a small, but significant, increase in hepatic SR-BI protein expression (2.16±0.32-fold, p = 0.01). None of the three transgenes altered the sinusoidal membrane-associated distribution of SR-BI determined by immunohistochemistry (Fig. 5, panels A, C, E and G), plasma cholesterol levels (left panels B in Figs. 2-4) or lipoprotein cholesterol size distribution profiles determined by FPLC (circles in panels C of Figs. 2-4). Thus, these mutated transgenes did not produce substantial dominant negative effects when overexpressed in WT mice (an example of a dominant negative truncated PDZK1 is described in (24)).

**Effects of mutant PDZK1 constructs in PDZK1 KO mice.** As previously described (8,23,24,41), absence of PDKZ1 expression in non-transgenic PDZK1 KO mice resulted in a dramatic loss of hepatic SR-BI protein (panels A in Figs. 2-4 and Fig. 5B), increased plasma total cholesterol (black bars in right panels B in Figs. 2-4) and an increase in the size of HDL particles (leftward shift in lipoprotein profiles, black squares in panels C in Figs. 2-4). All of these abnormalities are corrected by hepatic expression of a wild-type PDZK1 transgene in otherwise PDKZ1 KO animals (24). Hepatic transgenic expression of the PDZ2→1, ΔPDZ2 and ΔPDZ3 mutants in PDZK1 KO mice also corrected all of these abnormalities (Figs. 2-4, Fig. 5D, F and H, and Table I). Thus, a PDZK1
Molecular analysis of the PDZ4 domain of PDZK1

transgene containing a deletion of either the PDZ2 or PDZ3 domain can promote essentially full normalization of hepatic SR-BI steady state expression, localization and function. PDZK1 mutants with only three PDZ domains (PDZ1 and PDZ4 with either PDZ2 or PDZ3) could restore normal SR-BI activity as can the four PDZ domain containing full length PDZK1 (Fig. 1A) and the C-terminally truncated PDZ1234 (Fig. 1C). Thus, the spacing between the PDZ1 and PDZ4 domains in the linear sequence (compare PDZ2→1 to ΔPDZ2, Fig. 1D and E) does not appear to play a critical role in the regulation of hepatic SR-BI.

**Mechanism by which the PDZ4 domain influences hepatic SR-BI.** We previously showed that a C-terminally truncated PDZK1 containing only the first three N-terminal PDZ domains (PDZ123, Fig. 1B) is unable to restore full, normal expression and function of SR-BI in PDZK1 KO mice, whereas a truncated PDZK1 transgene containing all four PDZ domains (PDZ1234, Fig. 1C) can do so (23). Thus, even though PDZ4 does not bind directly to SR-BI’s C-terminus (19), this domain in PDZK1 performs a critical role(s) in promoting normal SR-BI protein expression and activity.

To further explore the role of the PDZ4 domain, we examined by immunohistochemistry using an anti-PDZK1 polyclonal antibody the cellular distribution of PDZK1, PDZ1234 and PDZ123 in hepatocytes in liver sections. Fig. 6A shows that in WT mice immunoperoxidase staining of endogenous PDZK1 exhibited a cell surface membrane-associated distribution similar to that seen for SR-BI (compare with Fig. 5A and (8,19,23)). This staining is absent in non-transgenic PDZK1 KO liver (Fig. 6B), indicating that the staining was PDZK1-specific. PDZ1234 in the liver of PDZK1 KO mice expressing a PDZ1234 transgene (23) (approximately 10-fold greater PDZ1234 protein than PDZK1 in WT liver, see Methods) exhibited a similar cell surface membrane-associated distribution (Fig. 6D). Strikingly, in the livers of PDZK1 KO mice expressing a PDZ123 transgene (approximately 8-fold greater PDZ123 protein than PDZK1 in WT liver, see Methods), we detected little cell surface-membrane-association (Fig. 6C, although there was clearly a significant level of intracellular staining relative to the negative control (Fig. 6B). Thus, the PDZ4 domain of PDZK1 appears to be necessary for this adaptor to associate robustly with the cell surface membrane of hepatocytes in vivo.

Additional analysis suggests that the PDZ4 domain is not sufficient for this membrane association. We examined the localization of endogenous PDZK1 in livers from mice with heterozygous (Fig. 6F) or homozygous (Fig. 6G) null mutations of SR-BI, as well as the amount of PDZK1 in the livers. Immunoblotting analysis (Fig. S1 and data not shown) indicates that the absence of SR-BI does not alter the levels of endogenous PDZK1. However, unlike the WT-like intracellular distribution of PDZK1 in heterozygous null SR-BI mice (Fig. 6F), there was little, if any, cell surface membrane-association of endogenous PDZK1 in homozygous null SR-BI KO mice (Fig. 6G). These immunohistochemical localization results suggest that both SR-BI and the PDZ4 domain of PDZK1 are required for robust cell surface membrane-association of PDZK1. They also raise the possibility that the PDZ4 domain may be required for normal regulation of SR-BI by virtue of its ability to influence PDZK1’s subcellular distribution.

Given the scaffold function of many multiple PDZ-domain containing proteins (20), it seemed possible that PDZK1 might mediate cell surface membrane localization and regulate SR-BI by linking SR-BI (while bound to PDZ1 or PDZ3) to some other protein whose C-terminus binds in the canonical peptide binding site of PDZ4. To test this possibility, we first generated and tested in vitro the binding activities of a set of mutant recombinant PDZ4 proteins and full-length PDZK1 proteins to identify a mutation that would abrogate classic C-terminal peptide binding. We then generated transgenic mice expressing full-length PDZK1 with a C-terminal peptide-binding-negative mutation in the PDZ4 domain (Fig.1G) and characterized in the transgenic animals its subcellular localization in the liver and its influence on SR-BI expression and activity.

**ITC analysis of the effects of amino acid substitutions within the carboxylate-binding loop of PDZ4 on classic C-terminal peptide binding.** The C-terminus of the transient receptor potential cation channel subfamily C member 5 (TRPC5) was previously identified as a target of the PDZ4 domain of PDZK1 (42). We
generated in E. coli and purified a group of wild-type and mutant recombinant PDZ4 domains and used isothermal calorimetry (ITC) to measure their binding to a peptide with the sequence of the C-terminus of TRPC5: 969EQVTTRL 975 (‘target peptide’). The amino acid substitutions in the carboxylate binding loops of these mutants included single residue substitutions (Y^388A, G^389P or G^389A) or double residue substitutions (Y^388G + G^389P, Y^388A + G^389A, or Y^388A + G^389P). The Y^388A substitution was made because the analogous substitution in the PDZ1 and PDZ3 domains prevents binding of a C-terminal peptide from SR-BI to these domains (18,19). Substitutions at 389G were made because this residue is one of the most highly conserved in the PDZ superfamily of proteins and larger side chains are expected to disrupt target peptide binding (1).

The results of the ITC analyses are shown in Table II and selected titration binding curves are shown in Figure 7. The TRPC5 target peptide bound to wild-type recombinant PDZ4 with a Kd of 10.8±0.6 µM (Fig. 7A). The single Y^388A substitution increased the Kd of target peptide binding by >10-fold, but the residual binding was too high to permit definitive conclusions to be drawn from previously reported in vivo, transgenic mouse functional studies that employed this mutation incorporated into the full length PDZK1 (PDZK1[Y^388A]) (19). Transgenic mice overexpressing PDZK1[Y^388A] (18-29-fold above that of endogenous PDZK1 in wild-type mice) can complement the defective hepatic SR-BI phenotypes in PDZK1 KO mice (19); however the residual binding activity of the PDZ4 domain might have been responsible for this activity. There was also residual binding activity for PDZ4 with a single G^389A substitution (Table II). In contrast, the G^389P substitution, singly or in combination with 388Y substitutions, completely blocked binding (Fig. 7B). Therefore, we incorporated the single G^389P substitution into full-length PDZK1 (PDZK1[G^389P]) and compared binding of the target peptide to this mutant with that to full-length, wild-type PDZK1 and to the C-terminally truncated PDZ123 protein (Fig. 1B) that does not contain the PDZ4 domain (all recombinant proteins generated in E. Coli). Figure 7C-E shows that the binding affinities of TRPC5 target peptide to all three proteins were similar, with Kd’s ranging from 7.8 to 12.3 µM; although the approximate number of binding sites for WT PDZK1 (N=2.17±0.03) was almost twice that of either PDZK1[G^389P] (N=1.37±0.01) or PDZ123 (N=1.40±0.02). These results suggest that there are two binding sites with similar affinities for the TRPC5 target peptide in WT PDZK1 and that the binding site on the PDZ4 domain is lost when that domain is removed (PDZ123) or when ^389Gly is replaced by a Pro. We conclude that expression of the PDZK1[G^389P] mutant as a transgene would permit evaluation of the role of classic target peptide binding to PDZ4 in PDZK1’s regulation of hepatic SR-BI in vivo.

In vivo activity of the PDZK1[G^389P] transgene We established two founder lines with the PDZK1[G^389P] transgene that expressed the mutant protein at either 14.3±1.0-fold (founder 8743) or 22.4±4.7-fold (founder 8744) above normal endogenous WT PDZK1 levels (Table I). These founders were used to generate matched wild-type (WT-Tg) and PDZK1 KO (KO-Tg) transgenic mice on a mixed FVB/129SvEv background. Background matched nontransgenic WT and PDZK1 KO mice were used as controls for each founder. The corresponding WT and KO transgenic mice derived from each of these two founders exhibited similar phenotypes. The results are shown in Figures 5 (I and J) and 8. In the WT background the hepatic SR-BI protein levels (Fig. 8A) and distributions (Fig. 5, panel I), plasma cholesterol levels (Fig. 8B) and lipoprotein size distributions (Fig. 8C) were unchanged by the transgene. Thus the transgene did not exhibit dominant-negative effects. All of the SR-BI-associated phenotypic abnormalities were corrected by hepatic expression of the PDZK1[G^389P] transgene in otherwise PDKZ1 KO animals (Fig. 5, panel J, and Fig. 8). Furthermore, the subcellular distribution of the PDZK1[G^389P] in PDZK1 KO mouse liver (Fig. 6E) was similar to that of WT PDZK1 in WT mice (Fig. 6A). Therefore we conclude that both PDZ4-mediated cell surface membrane localization of PDZK1 and the mechanism by which PDZ4 contributes to PDZK1’s regulation of hepatic SR-BI do not involve canonical binding of a target protein’s C-terminus to the canonical target peptide binding site of PDZ4.

The correlation of the PDZ4-dependent cell surface membrane localization of PDZK1 and its mutants with the regulation of hepatic SR-BI is
consistent with the possibility that PDZ4 might mediate this regulation as a consequence of mediating PDZK1’s association with the cell surface membrane. We explored this possibility by examining using biophysical techniques in vitro three potential mechanisms by which PDZ4 might influence the intracellular distribution of PDZK1: 1) PDZ4-mediated homo-oligomerization of PDZK1, 2) PDZ4-induced conformational changes in the PDZ123 portion of PDZK1, and 3) PDZ4-mediated binding to the phospholipids in the inner leaflet of the plasma membrane.

Analytical ultracentrifugation examination of PDZK1 oligomerization: Several reports have suggested that PDZ domain-containing proteins, including PDZK1, may be able to dimerize due to intermolecular associations, such as domain swapping or interdomain associations (19,43-47) (see below for additional discussion). Therefore we considered the possibility that the PDZ4 domain might mediate homo-oligomerization of PDZK1, and in so doing influence its membrane association and regulation of SR-BI. We used analytical ultracentrifugation to determine the extent of homo-oligomerization of recombinant full-length PDZK1. Figure 9 shows the results of sedimentation velocity analysis with essentially no observable concentration dependence of the normalized sedimentation patterns indicating that under these conditions there was only very weak (arrow), if any, intermolecular self-association of PDZK1 molecules. Global Lamm equation curve fitting to these data with SEDANAL gave a molar mass of 54,000 g/mol with no indication of self-association under these conditions. Lalonde and Bretcher have also reported weakly interacting, modest homodimerization of PDZK1 (47) mediated by the PDZ3, but not the PDZ4 domain. It is possible that the absence of strong intermolecular self-association seen in vitro does not reflect PDZK1’s status in vivo. However, if the lack of significant homodimerization of PDZK1 in vitro reflects its state in vivo, it seems unlikely that PDZ4 mediates homo-oligomerization in vivo and thus influences SR-BI regulation via such oligomerization.

Analysis of the influence of PDZ4 on the conformation of PDZ123 using hydrogen/deuterium exchange mass spectrometry (HXMS): We examined another mechanism by which PDZ4 might potentiate the activity of the otherwise not fully active PDZ123 (Fig. 1B) portion of PDZK1. It seemed possible that the presence of the PDZ4 domain at the C-terminus of the PDZ1234 protein (Fig. 1C) might alter the conformation of the SR-BI binding PDZ123 portion of the PDZ1234 protein, consequently conferring the ability of PDZ1234 to regulate SR-BI activity normally. To explore this possibility, we used the highly sensitive HXMS technique to assess the effects of the PDZ4 domain on the conformation of the PDZ123 portion of PDZ1234. The conformation of a protein and its interaction with other proteins can substantially influence the ability of backbone amide hydrogens to productively exchange with hydrogen/deuterium atoms in the solvent milieu. Our expectation was that substantial conformational changes in the PDZ123 portion of PDZ1234 relative to PDZ123 alone would be reflected in significant relative differences in deuterium exchange for at least some of the peptides common to the two proteins.

We individually incubated PDZ123 (residues 1-359) and PDZ1234 (1-458) from 10 sec to 4 hr at 21°C in buffer A containing deuterated water, then quenched the exchange reactions with low pH (2.5) and temperature (0°C), digested the proteins into peptides and used tandem mass spectrometry to identify peptides that correspond to 98.2% of the predicted full-length sequences (Supplemental Fig. S2). The relative amounts of deuterium incorporated into each peptide were determined for PDZ123 and PDZ1234 at each incubation time (Supplemental Fig. S3). Using these data, we calculated the difference in deuterium incorporation for the common peptides detected in both PDZ123 and PDZ1234, which spanned residues 1-337 (bar graph in Fig. 10). In Figure 10, bars to the left of the zero baseline in the center of the figure represent deuterium incorporation that was greater in PDZ123 than PDZ1234, with the reverse for bars to the right. Notably, the differences obtained for all shared peptides of the two proteins were below 0.4 Da (green vertical dashed lines in Fig. 10), the threshold for meaningful differences in HXMS measurements of this type (31,32). The data in Figure 10 clearly show that there were no significant changes in deuterium incorporation between the common regions of PDZ123 and
PDZ1234 (residues 1-337) as measured by HXMS. We cannot exclude the possibility that interaction between PDZ4 and the PDZ123 region is governed primarily by side chain-side chain interactions, and that those interactions might not influence backbone amide hydrogen exchange. However it seems more likely that the presence of PDZ4 does not induce substantial conformational changes within the PDZ123 region of PDZ1234. Thus, such PDZ4-induced conformational changes may not be responsible for PDZ4’s influence on the localization and in vivo activity of PDZK1.

Analysis of the membrane binding activity of PDZ4 using Surface Plasmon Resonance (SPR): Because we obtained in vivo or in vitro data suggesting that protein-protein interactions mediated by PDZ4 were not responsible for its influence on PDZK1’s regulation of hepatic SR-BI, we examined the ability of PDZ4 to mediate protein/lipid interactions. There are several reports that that PDZ domains can directly bind to membrane lipids (36,48,49) and thus mediate protein/membrane interactions. Such interactions may play an important part in the mechanisms underlying the functions of some PDZ domain-containing proteins. Since PDZK1 interacts with proteins located in the plasma membrane, we decided to test the ability of PDZ4 to interact with lipids in the inner plasma membrane. We thus measured the binding of PDZ4 and other PDZ domains from PDZK1 to vesicles whose lipid composition mimics that of the inner leaflet of the plasma membrane of mammalian cells (50). We previously reported that PDZ1, PDZ2 and PDZ3 domains from PDZK1 do not individually bind to such vesicles (36). Here we measured the binding of individual, recombinant PDZ4 and PDZ3 domains to plasma membrane mimetic vesicles. The sensorgrams in Fig. 11A (left) show the time courses of binding to the lipid vesicles at the indicated domain concentrations. The sensorgrams show that there was essentially no significant binding of the PDZ3 domain, as previously reported (36), whereas there was a dose dependent binding of PDZ4. Figure 11A (right) shows that the concentration dependence of maximal binding (RU) for PDZ4 is well-represented by a Langmuir-type saturation binding curve with an apparent $K_d$ of 1.2±0.1 μM. Fig. 11B shows similar results for the binding of recombinant proteins containing either only the first three PDZ domains (PDZ123, left panel, no significant binding) or all four PDZ domains (PDZ1234) (left and right panels, significant binding with an apparent $K_d$ of 1.1±0.1 μM that is virtually identical to that of the PDZ4 domain alone). These data suggest that the in vitro membrane binding activity of PDZ1234 is mediated by PDZ4. Taken together with the in vivo cell surface membrane localization results in Fig. 6, the in vitro membrane binding studies strongly suggest that that PDZ4-mediated binding of PDZK1 to cell surface inner membrane lipids may underlie the ability of PDZ4 to confer on PDZ1234 the ability to fully regulate the expression, localization and function of SR-BI in hepatocytes in vivo (23).

Discussion

PDZK1 is a four PDZ domain-containing, adaptor protein that controls the expression, localization and function of several membrane-associated proteins, among them the HDL receptor SR-BI in the liver (8). PDZK1 is normally concentrated at cell surface membranes in hepatocytes in vivo and this concentration depends on the presence of SR-BI (this study). Using transgenic mice, we have shown that the PDZ2 or PDZ3 domains can be deleted without abrogating PDZK1-mediated in vivo regulation of hepatic SR-BI protein expression, intracellular distribution and function as an HDL receptor. The results for the ΔPDZ3 construct are consistent with our previous study that showed inactivation of the canonical target peptide binding site on PDZ3 did not prevent essentially normal PDZK1-dependent regulation of hepatic SR-BI (19). The results also suggest that neither the PDZ2 nor PDZ3 domains play functionally important roles as spacers, maintaining appropriate separation of the other portions of the protein. Because PDZK1 is a multifunctional adaptor protein that interacts with many membrane proteins (2,6), it is not surprising that two of its four PDZ domains would not be essential for one of its functions – regulation of hepatic SR-BI.

Although the fourth PDZ domain (PDZ4) of PDZK1 does not bind to the C-terminus of SR-BI (19), it appears to be essential for normal PDZK1-mediated regulation of hepatic SR-BI in mice – hepatic expression of PDZ1234 fully corrects all
molecular analysis of the PDZ4 domain of PDZK1

hepatic SR-BI related abnormal phenotypes in PDZK1 KO mice, whereas hepatic expression of PDZ123, only partially corrects these abnormalities (24). The PDZ4 domain also appears to be necessary for the normal cell surface membrane localization of PDZK1 (this study). We have used a combination of in vivo transgenic mice and in vitro biochemical and biophysical approaches to explore the role of PDZ4. For example, we examined the in vivo localization and function of PDZK1 with a point mutation in PDZ4 that prevents its binding to the C-terminus of target proteins via its canonical peptide binding site. This analysis established that PDZK1 localization and function are independent of target protein binding via this site (protein scaffold mechanism). Our in vitro studies also appear to exclude a role for PDZ4 in mediating robust oligomerization of PDZK1 and thus its bound SR-BI (PDZ4-mediated oligomerization) or altering substantially the conformation of the PDZ123 portion of PDZK1 (conformational activation). However, we have discovered a new activity of PDZ4 that provides an attractive explanation for the mechanism by which this domain mediates the cell surface membrane localization of PDZK1 and PDZK1’s regulation of the activity of SR-BI (23). PDZ4 binds directly to phospholipids membranes that mimic the composition of the inner leaflet of the plasma membrane. The PDZ4-mediated binding of PDZK1 to lipids in the inner leaflet of the plasma membrane would increase the juxtamembrane concentration of PDZK1 and thus facilitate its interactions with SR-BI (PDZ4-mediated membrane proximity activation).

LaLonde and Bretscher previously reported studies of PDZK1 that are directly relevant to the work reported here. They described detailed analyses of intramolecular and intermolecular (homodimerization) PDZK1 interactions (47). They observed modest (weak) homodimerization of PDZK1 detected in cultured cells by co-immunoprecipitation of overexpressed, epitope tagged forms of PDZK1, and in vitro by chemical crosslinking (0.1% glutaraldehyde) of purified recombinant PDZK1. The modest homodimerization they observed might correspond to the very weak intermolecular self-association we observed using analytical ultracentrifugation, although it is difficult to directly compare the results of these very different methods. The oligomerization they detected was mediated by the PDZ3 domain. Our observation of essentially full in vivo activity of a ΔPDZ3 protein suggests that any modest PDZ3-dependent homodimerization of PDZK1 in vivo is not required for effective PDZK1-mediated regulation of hepatic SR-BI, although it may contribute to other in vivo functions of PDZK1. LaLonde and Bretscher also reported that a recombinant, N-terminally truncated portion of PDZK1 comprising only the PDZ4 domain and the remaining C-terminal residues does not dimerize in vitro (chemical crosslinking assay). These findings provide additional support for the proposal that intermolecular PDZ4-PDZ4 interactions are unlikely to mediate oligomerization that is functionally relevant to the hepatic regulation of SR-BI. Our conclusion that mechanism PDZ4-mediated oligomerization is unlikely appears to be consistent with the results of LaLonde and Bretscher (47).

LaLonde and Bretscher also reported that an intramolecular interaction between the C-terminus of PDZK1 and its PDZ1 domain can induce “the protein to adopt a more compact conformation” (47). The formation of the compact conformation that they detected using native PAGE depended on the presence of both the C-terminus of PDZK1 and an intact carboxylate binding loop in the PDZ1 domain. We have previously reported that deletion of the C-terminus of PDZK1 or inactivating the carboxylate binding loop in the PDZ1 domain does not prevent full PDZK1-mediated regulation of hepatic SR-BI (23). Thus, formation of the compact conformation of PDZK1 reported by LaLonde and Bretscher apparently is not required for PDZK1-mediated regulation of hepatic SR-BI, although it may contribute to other in vivo functions of PDZK1.

Future studies will be required to define in greater detail the PDZ4-mediated membrane proximity activation mechanism for the in vivo subcellular localization of PDZK1 and its promotion of normal expression, localization and function of hepatic SR-BI. In future work, the reagents and methods used in the current study may help establish if PDZK1’s PDZ2, PDZ3 or PDZ4 domains influence this adaptor’s other activities, such as mediating SR-BI signaling in endothelial cells (22,51) or the activities of other membrane proteins (e.g., CFTR, CFEX or...
Our results suggest that not all of the PDZ domains of a multifunctional, multi-PDZ domain-containing adaptor protein are required for each of its biological activities and that both the canonical target peptide binding and non-canonical (lipid binding) capacities of PDZ domains may be employed by a single such adaptor for optimal in vivo activity.

References:

1. Pawson, T., and Nash, P. (2003) Science 300, 445-452
2. Kocher, O., and Krieger, M. (2009) Curr Opin Lipidol. 20, 236-241
3. van Ham, M., and Hendriks, W. (2003) Mol Biol Rep. 30, 69-82
4. Doyle, D. A., Lee, A., Lewis, J., Kim, E., Sheng, M., and MacKinnon, R. (1996) Cell 85, 1067-1076
5. Kocher, O., Comella, N., Tognazzi, K., and Brown, L. F. (1998) Lab. Invest. 78, 117-125
6. Yesilaltay, A., Kocher, O., Rigotti, A., and Krieger, M. (2005) Curr Opin Lipidol 16, 147-152
7. Ikemoto, M., Arai, H., Feng, D., Tanaka, K., Aoki, J., Dohmae, N., Takio, K., Adachi, H., Tsujimoto, M., and Inoue, K. (2000) Proc Natl Acad Sci U S A 97, 6538-6543
8. Kocher, O., Yesilaltay, A., Cirovic, C., Pal, R., Rigotti, A., and Krieger, M. (2003) J Biol Chem 278, 52820-52825
9. Nakamura, T., Shibata, N., Nishimoto-Shibata, T., Feng, D., Ikemoto, M., Motojima, K., Iso-o, N., Tsukamoto, K., Tsujimoto, M., and Arai, H. (2005) Proc Natl Acad Sci U S A 102, 13404-13409
10. Rigotti, A., Miettinen, H., and Krieger, M. (2003) Endocrine Reviews 24, 357-387
11. Krieger, M. (1999) Annu. Rev. Biochem. 68, 523-558
12. Morrison, J., Silvestre, M., and Pittman, R. (1994) J Biol Chem. 269, 13911-13918
13. Rigotti, A., Trigatti, B. L., Penman, M., Rayburn, H., Herz, J., and Krieger, M. (1997) Proc Natl Acad Sci U S A 94, 12610-12615
14. Plump, A., Smith, J., Hayek, T., Aalto-Setala, K., Walsh, A., Verstuyt, J., Rubin, E., and Breslow, J. (1992) Cell 71, 343-353
15. Zhang, S., Reddick, R., Piedrahita, J., and Maeda, N. (1992) Science 258, 468-471
16. Braun, A., Trigatti, B. L., Post, M. J., Sato, K., Simons, M., Edelberg, J. M., Rosenberg, R. D., Schrenzel, M., and Krieger, M. (2002) Circ Res 90(3), 270-276
17. Trigatti, B., Rayburn, H., Vinals, M., Braun, A., Miettinen, H., Penman, M., Hertz, M., Schrenzel, M., Amigo, L., Rigotti, A., and Krieger, M. (1999) Proc Natl Acad Sci U S A 96, 9322-9327
18. Kocher, O., Birrane, G., Tsukamoto, K., Fenske, S., Yesilaltay, A., Pal, R., Daniels, K., Ladias, J., and Krieger, M. (2010) J Biol Chem 285, 34999-35010
19. Kocher, O., Birrane, G., Yesilaltay, A., Shechter, S., Pal, R., Daniels, K., and Krieger, M. (2011) J Biol Chem 286, 25171-25186
20. Pawson, T., and Scott, J. D. (1997) Science 278, 2075-2080
21. Kocher, O., Yesilaltay, A., Shen, C., Zhang, S., Daniels, K., Pal, R., Chen, J., and Krieger, M. (2008) Biochim Biophys Acta 1782, 310-316
22. Zhu, W., Saddar, S., Seetharam, D., Chambliss, K., Longoria, C., Silver, D. L., Yuhanna, I. S., Shaul, P. W., and Mineo, C. (2008) Circ Res 102, 480-487
23. Fenske, S., Yesilaltay, A., Pal, R., Daniels, K., Barker, C., Quinones, V., Rigotti, A., Krieger, M., and Kocher, O. (2009) J Biol Chem 284, 5797-5806
24. Fenske, S., Yesilaltay, A., Pal, R., Daniels, K., Rigotti, A., Krieger, M., and Kocher, O. (2008) J Biol Chem 283, 22097-22104
25. Simonet, W., Bucay, N., Lauer, S., and Taylor, J. (1993) J Biol Chem 268, 8221-8229
26. Stafford, W. (1994) Methods in Enzymology Numerical Computer Methods, Part B, Orlando, Academic Press, 478-501
27. Stafford, W. (2000) Methods Enzymol 323, 302-325
28. Stafford, W., and Sherwood, P. (2004) Biophysical Chemistry 108, 231-243
29. Stafford, W. F. (1992) Analytical Biochem. 203, 295-301
30. Wales, T., Fadgen, K., Gerhardt, G., and Engen, J. (2008) Anal Chem. 80, 6815-6820
31. Houde, D., Berkowitz, S., and Engen, J. (2011) J Pharm Sci. 100, 2071-2086
32. Iacob, R., and Engen, J. (2012) J Am Soc Mass Spectrom. 23, 1003-1010
33. Iacob, R., Pene-Dumitrescu, T., Zhang, J., Gray, N., Smithgall, T., and Engen, J. (2009) Proc Natl Acad Sci U S A 106, 1386-1391
34. Zhang, Z., and Smith, D. (1993) Protein Sci. 2, 522-531
35. Chen, Y., Sheng, R., Källberg, M., Silkov, A., Tun, M., Bhardwaj, N., Kurilova, S., Hall, R., Honig, B., Lu, H., and Cho, W. (2012) Mol Cell. 46, 226-237
36. Stahelin, R., and Cho, W. (2001) Biochemistry 40, 4672-4678
37. Kocher, O., Pal, R., Roberts, M., Cirovic, C., and Gilchrist, A. (2003) Mol Cell Biol 23(4), 1175-1180
38. Palmeter, R., and Brinster, R. (1986) Annu Rev Genet 20, 465-499
39. Guo, Q., Penman, M., Trigatti, B., and Krieger, M. (1996) J Biol Chem 271, 11191-11196
40. Yesilaltay, A., Kocher, O., Pal, R., Leiva, A., Quinones, V., Rigotti, A., and Krieger, M. (2006) J Biol Chem 281, 28975-28980
41. Stiffler, M., Chen, J., Grantcharova, V., Lei, Y., Fuchs, D., Allen, J., Zaslavksaia, L., and MacBeath, G. (2007) Science 317, 364-369
42. Fanning, A., Lye, M., Anderson, J., and Lavie, A. (2007) J Biol Chem 282 37710-37716
43. Im, Y., Lee, J., Park, S., Park, S., Rho, S., Kang, G., Kim, E., and Eom, S. (2003) J Biol Chem 278, 48099-48104
44. Im, Y., Park, S., Rho, S., Lee, J., Kang, G., Sheng, M., Kim, E., and Eom, S. (2003) J Biol Chem 278, 8501-8507
45. Kocher, O., Comella, N., Gilchrist, A., Pal, R., Tognazzi, K., Brown, L. F., and Knoll, J. H. M. (1999) Lab Invest 79, 1161-1170
46. Lalonde, D., and Bretscher, A. (2009) Biochemistry 48, 2261-2271
47. Zimmermann, P. (2006) Biochim Biophys Acta. 1761, 947-956
48. Feng, W., and Zhang, M. (2009) Nat Rev Neurosci. 10, 87-99
49. Stahelin, R., Long, F., Peter, B., Murray, D., De Camilli, P., McMahon, H., and Cho, W. (2003) J Biol Chem. 278, 28993-28999
50. Mineo, C., and Shaul, P. (2012) Curr Opin Lipidol. 23, 487-493
Molecular analysis of the PDZ4 domain of PDZK1

52. Thomson, R., Wang, T., Thomson, B., Tarrats, L., Girardi, A., Mentone, S., Soleimani, M., Kocher, O., and Aronson, P. (2005) Proc Natl Acad Sci U S A 102, 13331-13336

53. Wang, P., Wang, J., Xiao, Y., Murray, J., Novikoff, P., Angeletti, R., Orr, G., Lan, D., Silver, D. L., and Wolkoff, A. (2005) J Biol Chem 280, 30143-30149

54. Wang, S., Yue, H., Derin, R., Guggino, W., and Li, M. (2000) Cell 103, 169-179

55. Kavan, D., and Man, P. (2011) Int. J. Mass Spectrom. 302, 53–58

FOOTNOTES

We thank Joel Lawitts from the BIDMC transgenic facility and Debby Pheasant from the MIT Biophysical Instrumentation Facility for helping with the ITC experiments and Verna Frasca from Microcal for helping with analysis and interpretation of the ITC data. This work was supported by grants from the National Institutes of Health HL077780 (OK), HL52212 and HL66105 (MK), GM68849 (WC), GM086507 and GM101135 (JRE) and a research collaboration with the Waters Corporation (JRE).

The abbreviations used are: WT, wild-type; KO, knockout; SR-BI, scavenger receptor class B type I; CBL, carboxylate binding loop; EGFP, enhanced green fluorescent protein; FPLC, fast protein liquid chromatography; HDL, high-density lipoprotein; HXMS, hydrogen/deuterium exchange mass spectrometry; ITC, isothermal titration calorimetry; POPC, 1 palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; POPE, 1 palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine; POPS, 1 palmitoyl-2-oleoyl-sn-glycero-3-phosphoserine; PI, phosphoinositol; PtdIns(4,5)P2, 1,2-dipalmitoyl derivatives of phosphatidylinositol-(4,5)—biphosphonate; SPR, surface plasmon resonance; Tg, transgene.

Figure Legends

**Fig. 1.** Schematic diagrams of wild-type (A) and mutant (B-G) PDZK1 proteins. A. Full-length, wild-type PDZK1 with the PDZ domains that bind the C-terminus (C-term.) of SR-BI (PDZ1 and PDZ3) indicated. B. C-terminally truncated PDZ123. C. C-terminally truncated PDZ1234. D. Full-length protein with PDZ2 domain replaced by a duplication of the PDZ1 domain (speckled circle), PDZ2→1. E. PDZK1 with deletion of the PDZ2 domain (dashed line), ΔPDZ2. F. PDZK1 with deletion of the PDZ3 domain (dashed line), ΔPDZ3. G. Full-length PDZK1 with an inactivating G389P mutation in the canonical target peptide binding site of the PDZ4 domain (yellow), PDZK1[G389P].

**Fig. 2.** Effects of expression of the PDZ2→1 transgene on hepatic SR-BI protein levels (A) and plasma lipoprotein cholesterol (B and C) in WT and PDZK1 KO mice. A. Liver lysates (~30 µg of protein) from mice with the indicated genotypes, with (+) or without (-) the PDZ2→1 transgene (Tg) (replacement of the PDZ2 domain with a second PDZ1 domain, see Figure 1D) were analyzed by immunoblotting (data from founder 8419), and bands representing PDZK1 (~70 kDa) and SR-BI (~82 kDa) were visualized by chemiluminescence. ε-COP (~34 kDa) was used as a loading control. Note there is a faint SR-BI band in the nontransgenic PDZK1 KO lane. Replicate experiments with multiple exposures and sample loadings were used to determine the relative levels of expression of SR-BI (Table II). B. Plasma samples were harvested from mice with the indicated genotypes and PDZ2→1transgene. Total plasma cholesterol levels were determined in individual samples by enzymatic assay, and mean values from the indicated numbers of animals (n) are shown for each genotype. Independent WT and KO control animals for each founder line were generated to ensure that the mixed genetic backgrounds for experimental and control mice were matched. Values from the two independent founder lines 8419 and 8418 were not statistically significantly different and thus were averaged together here. * Indicates the
Molecular analysis of the PDZ4 domain of PDZK1

nontransgenic KO plasma cholesterol levels were statistically significantly different from those plasma cholesterol levels of WT (p<0.0001). ** Indicates PDZK1 KO [PDZ2→1-Tg] plasma cholesterol levels were statistically significantly different from those plasma cholesterol levels of nontransgenic PDZK1 KO mice (p<0.0001). WT, WT [PDZ2→1-Tg] and KO [PDZ2→1-Tg] plasma cholesterol levels were not statistically significantly different. C. Pooled plasma samples (described in panel B) from four to five animals (data from founder 8419) were size-fractionated by FPLC, and the total cholesterol content of each fraction was determined by an enzymatic assay. The chromatograms are representative of multiple individually determined profiles. Approximate elution positions of native VLDL, IDL/LDL and HDL particles are indicated by brackets and were determined as previously described (13). The chromatograms for the WT, WT+Tg and KO+Tg are overlapping.

Fig. 3. Effects of expression of the ΔPDZ2 transgene on hepatic SR-BI protein levels (A) and plasma lipoprotein cholesterol (B and C) in WT and PDZK1 KO mice. A. Liver lysates (~30 µg of protein) from mice with the indicated genotypes, with (+) or without (−) the ΔPDZ2 transgene (Tg) (deletion of the PDZ2 domain, see Figure 1E) were analyzed by immunoblotting (data from founder 8421), and bands representing PDZK1 (~70 kDa for WT) and SR-BI (~82 kDa) were visualized by chemiluminescence. ε-COP (~34 kDa) was used as a loading control. Note the faint SR-BI band in the nontransgenic PDZK1 KO lane. Replicate experiments with multiple exposures and sample loadings were used to determine the relative levels of expression of SR-BI (Table II). B. Plasma samples were harvested from mice with the indicated genotypes and ΔPDZ2 transgene. Total plasma cholesterol levels were determined in individual samples by enzymatic assay, and mean values from the indicated numbers of animals (n) are shown for each genotype. Independent WT and KO control animals for the founder line were generated to ensure that the mixed genetic backgrounds for experimental and control mice were matched. Values from the two independent founder lines, 8421 and 8423 were not statistically significantly different and thus were averaged together here. * Indicates the nontransgenic KO plasma cholesterol levels were statistically significantly different from those plasma cholesterol levels of WT (p<0.0001). ** Indicates PDZK1 KO [ΔPDZ2-Tg] plasma cholesterol levels were statistically significantly different from those plasma cholesterol levels of nontransgenic PDZK1 KO mice (p<0.0001). WT, WT [ΔPDZ2-Tg] and KO [ΔPDZ2-Tg] plasma cholesterol levels were not statistically significantly different. C. Pooled plasma samples (described in panel B) from four to five animals (data from founder 8421) were size-fractionated by FPLC, and the total cholesterol content of each fraction was determined by an enzymatic assay. The chromatograms are representative of multiple individually determined profiles. Approximate elution positions of native VLDL, IDL/LDL and HDL particles are indicated by brackets and were determined as previously described (13). The chromatograms for the WT, WT+Tg and KO+Tg are overlapping.

Fig. 4. Effects of expression of the ΔPDZ3 transgene on hepatic SR-BI protein levels (A) and plasma lipoprotein cholesterol (B and C) in WT and PDZK1 KO mice. A. Liver lysates (~30 µg of protein) from mice with the indicated genotypes, with (+) or without (−) the ΔPDZ3 transgene (Tg) (deletion of the PDZ3 domain, see Figure 1F), were analyzed by immunoblotting (data from founder 8642), and bands representing PDZK1 (~70 kDa for WT) and SR-BI (~82 kDa) were visualized by chemiluminescence. ε-COP (~34 kDa) was used as a loading control. Note the faint SR-BI band in the nontransgenic PDZK1 KO lane. Replicate experiments with multiple exposures and sample loadings were used to determine the relative levels of expression of SR-BI (Table II). B. Plasma samples were harvested from mice with the indicated genotypes and ΔPDZ3 transgene. Total plasma cholesterol levels were determined in individual samples by enzymatic assay, and mean values from the indicated numbers of animals (n) are shown for each genotype. Independent WT and KO control animals for each founder line were generated to ensure that the mixed genetic backgrounds for experimental and control mice were matched. Values from the two independent founder lines, 8642 and 8640 were not statistically significantly different and thus were averaged together here. * Indicates the nontransgenic KO plasma cholesterol levels were statistically significantly different from those plasma cholesterol levels of WT (p<0.0001). ** Indicates PDZK1 KO
Molecular analysis of the PDZ4 domain of PDZK1

[ΔPDZ3-Tg] plasma cholesterol levels were statistically significantly different from those plasma cholesterol levels of nontransgenic PDZK1 KO mice (p<0.0001). WT, WT [ΔPDZ3-Tg] and KO [ΔPDZ3-Tg] plasma cholesterol levels were not statistically significantly different. C. Pooled plasma samples (described in panel B) from four to five animals (data from founder 8642) were size-fractionated by FPLC, and the total cholesterol content of each fraction was determined by an enzymatic assay. The chromatograms are representative of multiple individually determined profiles. Approximate elution positions of native VLDL, IDL/LDL and HDL particles are indicated by brackets and were determined as previously described (13). The chromatograms for the WT, WT+Tg and KO+Tg are overlapping.

**Fig. 5.** Immunohistochemical analysis of hepatic SR-BI in WT and PDZK1 KO nontransgenic (A and B), PDZ2→1 transgenic (C and D), ΔPDZ2 transgenic (E and F), ΔPDZ3 transgenic (G and H) and PDZK1[G389P] transgenic (I and J) mice. Livers from mice of the indicated genotypes and transgenes (Tg) were fixed, frozen and sectioned (data from the corresponding founders 8419, 8421, 8642 and 8743, respectively). The sections were then stained with a polyclonal anti-SR-BI antibody, and a biotinylated anti-rabbit IgG secondary antibody and visualized by immunoperoxidase staining. (Magnification x600).

**Fig. 6.** Immunohistochemical analysis of the subcellular localization of PDZK1 in hepatocytes in vivo. Livers were harvested from wild-type (WT) mice (A), nontransgenic PDZK1 KO mice (B), transgenic PDZK1 KO mice expressing in hepatocytes either PDZ123 (C), PDZ1234 (D), or PDZK1[G389P] (E), or heterozygous (F) or homozygous (G) null SR-BI KO mice. Livers were fixed, frozen and sectioned. The sections were then stained with a polyclonal anti-PDZK1 antibody, and a biotinylated anti-rabbit IgG secondary antibody and visualized by immunoperoxidase staining. (Magnification x600). Arrows indicate examples of cell surface membrane-associated staining.

**Fig. 7.** Isothermal titration calorimetric analysis of the binding of a C-terminal peptide from TRPC5 to PDZK1-derived recombinant proteins. The indicated individual recombinant wild-type and mutant PDZK1 variants (0.03 mM in 1.8 ml of 150 mM NaCl, 0.5 mM tris (2-carboxyethyl) phosphine, 25 mM Tris-pH 8.0) were placed in a titration cell and equilibrated at 20 °C. These proteins were: A. WT PDZ4 domain, B. PDZ4[G389P] domain, C. full-lengthWT-PDZK1, D. full-length PDZK1[G389P], and E. PDZ123. A solution containing 1.0 mM of the C-terminal heptapeptide from TRPC5, [396]EQVTTRL[389], was injected in 10 µl aliquots with an interval of 4 minutes between each addition to permit re-equilibration. Titration curves were analyzed and the values of $K_{d}$ and N (number of binding sites/molecule) were determined using ORIGIN 7.0 software.

**Fig. 8.** Effects of expression of the PDZK1[G389P] single mutant transgene on hepatic SR-BI protein levels (A) and plasma lipoprotein cholesterol (B and C) in WT and PDZK1 KO mice. A. Liver lysates (~30 µg of protein) from mice with the indicated genotypes, with (+) or without (-) the PDZK1[G389P] transgene (Tg) (inactivating single residue substitution in the PDZ4 domain, see Figure 1G) were analyzed by immunoblotting (data from founder 8744), and bands representing PDZK1 (~70 kDa) and SR-BI (~82 kDa) were visualized by chemiluminescence. ε-COP (~34 kDa) was used as a loading control. Note the faint SR-BI band in the nontransgenic PDZK1 KO lane. Replicate experiments with multiple exposures and sample loadings were used to determine the relative levels of expression of SR-BI (Table II). B. Plasma samples were harvested from mice with the indicated genotypes and PDZK1[G389P] transgene. Total plasma cholesterol levels were determined in individual samples by enzymatic assay, and mean values from the indicated numbers of animals (n) are shown for each genotype. Independent WT and KO control animals for each founder line were generated to ensure that the mixed genetic backgrounds for experimental and control mice were matched. Values from the two independent founder lines, 8744 and 8743 were not statistically significantly different and thus were averaged together here. * Indicates the nontransgenic KO plasma cholesterol levels were statistically
significantly different from those plasma cholesterol levels of WT (p<0.0001). ** Indicates PDZK1 KO [G\(^{389}\P\)] plasma cholesterol levels were statistically significantly different from those plasma cholesterol levels of nontransgenic PDZK1 KO mice (p<0.0001). WT, WT [G\(^{389}\P\)] and KO [G\(^{389}\P\)] plasma cholesterol levels were not statistically significantly different. C. Pooled plasma samples (described in panel B) from four to five animals (data from founder 8743) were size-fractionated by FPLC, and the total cholesterol content of each fraction was determined by an enzymatic assay. The chromatograms are representative of multiple individually determined profiles. Approximate elution positions of native VLDL, IDL/LDL and HDL particles are indicated by brackets and were determined as previously described (13). The chromatograms for the WT, WT+Tg and KO+Tg are overlapping.

**Fig. 9.** Sedimentation velocity ultracentrifugation analysis of PDZK1. Sedimentation velocity profiles of PDZK1 were determined at three different concentrations: 1.803 (red), 0.453 (blue), 0.212 (green) mg/ml. No observable concentration dependence of the normalized sedimentation patterns was seen, indicating that under these conditions there was only very weak, if any, intermolecular self-association of PDZK1 molecules. Vertical axis: normalized sedimentation pattern, g(s*)/Co; horizontal axis: apparent sedimentation coefficient, s*. The slight shift (arrow) towards higher s* values may reflect a very weak self-association under these conditions. However, global fitting of these data to a single species model did not indicate the presence of significant amount of dimer at 1.8 mg/mL.

**Fig. 10.** Comparison of the conformations of the PDZ123 regions of PDZ123 and PDZ1234 using Hydrogen/deuterium exchange mass spectrometry. Recombinant PDZ123 (residues 1-359) and PDZ1234 (1-458) proteins that also included two additional N-terminal residues (\(^{15}\)G and \(^{15}\)S, from the cloning vector) were incubated for 10 sec (orange), 10 minutes (red), 1 hour (blue) or 4 hours (black) in buffer A containing deuterated water. The proton/deuterium exchange reactions were then quenched with low pH (2.5) and temperature (0 °C), the proteins digested into peptides and the average amounts of deuterium incorporated was determined using mass spectrometry. We identified peptides corresponding to 98.2% of the predicted full-length PDZ1234 sequence (Supplemental Figure S2, created using MSTools (55)). Deuterium incorporation plots for the individual peptides presented here are shown in Supplemental Figure S3. The differences in deuterium incorporation for each of the indicated peptides (PDZ1234-PDZ123) at each time of incubation are expressed in Daltons (Da). The error limit for the determination of deuterium incorporation is +/- 0.4 Da (indicated with vertical dashed green lines (31)).

**Fig. 11.** Determination of the binding of recombinant PDZ3, PDZ4, PDZ123 and PDZ1234 to plasma membrane mimetic vesicles by equilibrium SPR analysis. A. Left panel: Sensorgrams of the time courses of binding of PDZ3 (2 µM, broken line) and PDZ4 (0.25, 0.5, 1, 2, 3 and 5 µM, lowest to highest sensorgarm responses, respectively). Equilibrium SPR measurements were performed in 20 mM Tris-HCl, pH 7.4, containing 0.16 M NaCl. Proteins were injected over an L1 chip coated with PM-mimetic vesicles at 5 µl/min. For PDZ4, the membrane association was too slow for the sensorgrams to reach saturation within the injection period and thus the final RU values were arbitrarily taken as \(R_\text{eq}\). Right panel: Concentration dependence of binding of PDZ4 generated from \(R_\text{eq}\) values (averages of triplicate measurements). The solid line represents the curve determined by nonlinear least squares fit of the data to the equation \(R_\text{eq} = R_\text{max}/(1 + K_d/P_0)\), where \(P_0\) is the concentration of PDZ4 and \(R_\text{max} = 34 ± 2\) and \(K_d = 1.2 ± 0.1\) µM. B. Left panel: Sensorgrams of the time courses of binding of PDZ123 (2 µM, broken line) and PDZ1234 (0.25, 0.5, 1, 2, 3 and 5 µM, lowest to highest sensorgarm responses, respectively) as described above. Right panel: Concentration dependence of binding of PDZ1234 with the solid line representing the nonlinear least squares fit of the data (\(R_\text{max} = 38 ± 1\) and \(K_d = 1.1 ± 0.1\) µM).
Molecular analysis of the PDZ4 domain of PDZK1

Table I. Relative PDZK1 and SR-BI protein expression levels in transgenic (Tg) and non-transgenic mice.

| PDZK1 MUTANT | FOUNDER | Relative PDZK1 protein level | Relative SR-BI protein level$^§$ |
|-------------|---------|-----------------------------|---------------------------------|
|             |         | WT-Tg/WT                    | WT-Tg/WT                        |
|             |         | KO-Tg/WT                    |                                 |
| PDZ2→1      | 8419    | 5.40±0.61**                 | 2.16±0.32*                      |
|             | 8418    | 4.50±1.12**                 | 2.18±0.78*                      |
| Δ PDZ2      | 8421    | 17.15±4.66**                | 2.29±0.73*                      |
|             | 8423    | 16.59±1.57**                | 1.80±0.38*                      |
| Δ PDZ3      | 8642    | 2.45±0.46**                 | 1.33±0.21*                      |
|             | 8640    | 15.48±4.17**                | 0.85±0.33*                      |
| PDZK1[G389P]| 8743    | 14.25±1.02**                | 1.70±0.29*                      |
|             | 8744    | 22.39±4.69**                | 2.07±0.56*                      |

$^§$Averages including both founders

$^{**}$p values comparing WT-Tg vs WT ranged from 0.02 to <0.0001

*p > 0.05 for WT-Tg or KO-Tg vs WT

#p = 0.01 for WT-Tg vs WT

Table II. Isothermal titration calorimetric analysis of the binding of a C-terminal peptide from TRPC5 to full length and truncated PDZK1 recombinant proteins

|           | $K_d$ † | Number of binding sites |
|-----------|---------|-------------------------|
| PDZ4 (WT) | 10.8±0.6 μM | 1.07±0.02               |
| PDZ4[Y388A] | 151.1±27.6 μM | 1.80±0.54               |
| PDZ4[G389A] | 37.3±7.25 μM  | 0.49±0.20               |
| PDZ4[G389Y] | No binding    | N/A                     |
| PDZ4[G389P] | No binding    | N/A                     |
| PDZ4[Y388G+ G389P] | No binding    | N/A                     |
| PDZ4[Y388A+ G389A] | No binding    | N/A                     |
| PDZ4[Y388A+ G389P] | No binding    | N/A                     |
| PDZK1 (WT) | 12.3±0.8 μM   | 2.17±0.03               |
| PDZK1[G389P] | 7.8±0.3 μM    | 1.37±0.01               |
| PDZ123     | 10.2±0.6 μM   | 1.40±0.02               |

† peptide sequence: 969EQVTTRL975
Molecular analysis of the PDZ4 domain of PDZK1

Figure 1

A  SR-BI C-term. binding sites (PDZ1 & PDZ3)
    PDZK1  PDZ1  PDZ2  PDZ3  PDZ4  519  C

B  PDZ123  PDZ1  PDZ2  PDZ3  C

C  PDZ1234  PDZ1  PDZ2  PDZ3  PDZ4  C

D  PDZ2→1  PDZ1  PDZ1  PDZ3  PDZ4  C

E  ΔPDZ2  PDZ1  PDZ3  PDZ4  C

F  ΔPDZ3  PDZ1  PDZ2  PDZ4  C

G  PDZK1  PDZ1  PDZ2  PDZ3  PDZ4  C

[G^{389}P]
Molecular analysis of the PDZ4 domain of PDZK1

Figure 2

A. PDZ2→PDZ1-Tg SR-BI and PDZK1 levels

| PDZK1 Genotype | WT | KO |
|----------------|----|----|
| Tg             | −  | +  |
| PDZK1          | −  | +  |
| SR-BI          | −  | +  |
| ε-COP          | −  | +  |

B. PDZ2→PDZ1-Tg Plasma Cholesterol

| Plasma Cholesterol (mg/dl) |
|---------------------------|
| 0                         |
| 100                       |
| 200                       |

- **Tg**
  - WT: n=16
  - KO: n=16

- **WT**
  - n=10

- **KO**
  - n=17

C. PDZ2→PDZ1-Tg Lipoprotein Cholesterol Profiles

- **VLDL**
- **IDL/LDL**
- **HDL**

Cholesterol Content (mg/dl) vs. Fraction number
Figure 3

A. ΔPDZ2-Tg SR-BI and PDZK1 levels

| PDZK1 Genotype | WT  | KO  |
|----------------|-----|-----|
| Tg             | -   | +   |
| PDZK1          |     |     |
| SR-BI          |     |     |
| ε-COP          |     |     |

B. ΔPDZ2-Tg Plasma Cholesterol

| Plasma Cholesterol (mg/dl) |
|---------------------------|
| Tg                        |
| WT                        | n=14 |
| KO                        | n=11*|
| n=19**                    |

C. ΔPDZ2-Tg Lipoprotein Cholesterol Profiles

Cholesterol Content (mg/dl)

Fraction number
Molecular analysis of the PDZ4 domain of PDZK1

Figure 4

A. ΔPDZ3-Tg SR-BI and PDZK1 levels

|        | PDZK1 Genotype |
|--------|----------------|
|        | WT  | KO  |
| Tg     | -   | +   |
| PDZK1  |     |     |
| SR-BI  |     |     |
| e-COP  |     |     |

B. ΔPDZ3-Tg Plasma Cholesterol

|        | WT          | KO          |
|--------|-------------|-------------|
|        | n=11        | n=18        |
| Tg     | +           | +           |

C. ΔPDZ3-Tg Lipoprotein Cholesterol Profiles
Molecular analysis of the PDZ4 domain of PDZK1

Figure 5

|          | No Transgene | PDZ2→PDZ1-Tg | ΔPDZ2-Tg | ΔPDZ3-Tg | G\text{G}^{389}\text{P}-Tg |
|----------|--------------|--------------|----------|----------|--------------------------|
| **WT**   |              |              |          |          |                          |
| A        |              | C            | E        | G        | I                        |
| **KO**   |              |              |          |          |                          |
| B        |              | D            | F        | H        | J                        |
Molecular analysis of the PDZ4 domain of PDZK1

Figure 6
Molecular analysis of the PDZ4 domain of PDZK1

Figure 7

A. WT PDZ4

B. PDZ4[G389P]

Kd 10.8±0.6 μM
N=1.07±0.02

No binding

C. WT PDZK1

D. PDZK1[G389P]

Kd 12.3±0.8 μM
N=2.17±0.03

Kd 7.8±0.3 μM
N=1.37±0.01

E. PDZ123

Kd 10.2±0.6 μM
N=1.40±0.02
Molecular analysis of the PDZ4 domain of PDZK1

Figure 8

A. G^{389}P-Tg SR-BI and PDZK1 levels

| PDZK1 Genotype | WT | KO |
|----------------|----|----|
| Tg             | -  | +  |
| PDZK1          |    |    |
| SR-BI          |    |    |
| ε-COP          |    |    |

B. G^{389}P-Tg Plasma Cholesterol

|                      | WT | KO |
|----------------------|----|----|
| Tg                   | -  | +  |

C. G^{389}P-Tg Lipoprotein Cholesterol Profiles
Figure 9
Molecular analysis of the PDZ4 domain of PDZK1

Figure 10

Peptides

-2GSMASTFNPRE9
10CKLKSQEGQNN19
13SKQEGQNYGFF23
23FLRIEKDTDHHL34
35RVIEEGSPAEAQKL49
50LDGDRVLRINGF62
63VDKEEEHAQ70
70QVVEL74
74LVRKSNSSVTL84
86LVDGDS91
92YEKAVKNQVD101
102KELDQSQRE111
112AALNDKKPGPGMN125
126AVEPCAQPRLCY137
138LVKEGNSFG146
147FSLKTIQGKKGYY159
160LTIDMPQGVA169
170MKAGVL175
181IEVNGENVENASHE194
195EVVEKVTSGSRIMF209
210LLVDKETARC219
220HSEQKTQF227
228KRETASL234
235KLLPHQPRV243
244VVIKKGSNGYGF255
256YLRAgPEQKGGIIKD270
271IEPSAPAE278
279AAGLNNND286
287LVVAVNGKSVE297
298ALDHGVE306
307MRKGGDQTTLS317
318LVLDKEAESIYSL330
331ARFSPLL337

Relative Difference in Deuterium Incorporation, PDZ1234 – PDZ123 (Da)
Figure 11

A

B

Molecular analysis of the PDZ4 domain of PDZK1
Fig. S1. Liver lysates (~30 µg of protein) from mice with the indicated genotypes (heterozygous or homozygous null for SR-BI) were analyzed by immunoblotting, and bands representing SR-BI (~82 kDa) and PDZK1 (~70 kDa) were visualized by chemiluminescence. ε-COP (~34 kDa) was used as a loading control.
Fig. S2. Peptide map for the online digestion of PDZ1234 and PDZ123. The red bars below the sequence indicate the individual peptide fragments presented in Figure 10. The blue bars below the sequence indicate all of the individual peptide fragments for which there are deuterium incorporation data.
Molecular analysis of the PDZ4 domain of PDZK1
**Fig. S3.** Comparison of the relative deuterium incorporation for consecutive and coincident peptide fragments from PDZ1234 and PDZ123 (Figure 10 and red bars in Figure S2). The y axis in each graph represents relative deuterium level incorporated into each peptide over time measured at 10 seconds, 10 minutes, 1 hour and 4 hours for PDZ1234 (blue squares) and PDZ123 (red circles).